URL Pharma
URL Pharma is a pharmaceutical company with a 63-year history in manufacturing and distributing generic drugs, known for its branded products such as COLCRYS® and FIBRICOR™ and its advanced drug formulation technologies.
Company History
URL Pharma has a 63-year history in distributing and manufacturing generic drugs. The company has continued to evolve and grow, notably forming its branded and technology division in 2004. URL Pharma expanded its manufacturing capabilities through the acquisition of PharmPro assets in 2009, enhancing its technology base. Over the years, the company has maintained robust financial performance, supported by cumulative revenues exceeding $800MM from licensing deals.
NDA and ANDA Approvals
URL Pharma has received several significant approvals from the FDA. In 2009, the company achieved NDA approvals for Colcrys® and Fibricor™. Additionally, URL Pharma boasts 288 ANDA approvals, cementing its position as a major player in the generic drug market. These approvals highlight the company's commitment to bringing safe and effective medications to market.
Branded and Generic Products
URL Pharma currently markets four branded prescription medications: COLCRYS®, FIBRICOR®, Qualaquin®, and Bactrim™, under the AR Scientific, Inc. label. The company also has a strong presence in the generic segment, encompassing formulation development, manufacturing, and distribution. In 2005, URL Pharma manufactured 2.5 billion tablets and capsules, showcasing its industrial capacity.
Facilities and Manufacturing
URL Pharma operates manufacturing facilities located in Philadelphia. These facilities have consistently received clean FDA inspection reports (FDA-Form 483) over the last three years, underscoring their operational excellence. The acquisition of PharmPro assets in Chicago in 2009 further expanded the company's manufacturing technology base.
Technologies and Innovations
URL Pharma is at the forefront of pharmaceutical technology with innovations like Z-Burst™ zero-order release technology, NanoBurst™ nanoparticle technology, and MultiBurst™ multiparticulate technology. The company focuses on enhancing the safety and efficacy profiles of medicines through rigorous clinical studies and formulation development. This commitment to innovation is also seen in their robust pipeline of proprietary products at various stages of development.